<DrugInformationSummary id="CDR0000788795"><DrugInfoMetaData><DrugInfoType>Brief</DrugInfoType><DrugInfoAudience>Patients</DrugInfoAudience><DrugInfoDescription>This page contains brief information about durvalumab
         and a collection of links to more information about the use of 
         this drug, research results, and ongoing clinical trials.
  </DrugInfoDescription><DrugInfoURL xref="https://www.cancer.gov/about-cancer/treatment/drugs/durvalumab">Durvalumab</DrugInfoURL><FDAApproved>Yes</FDAApproved><TerminologyLink ref="CDR0000740856">durvalumab</TerminologyLink><GlossaryLink ref="CDR0000788775">durvalumab</GlossaryLink><USBrandNames><USBrandName>Imfinzi</USBrandName></USBrandNames><PronunciationInfo><TermPronunciation>dur-VAL-yoo-mab</TermPronunciation><MediaLink ref="CDR0000789270" type="audio/mpeg" alt="" language="en" id="_3"/><MediaLink ref="CDR0000789269" type="audio/mpeg" alt="" language="es" id="_4"/></PronunciationInfo><FDAExternalRef xref="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8baba4ea-2855-42fa-9bd9-5a7548d4cec3&amp;audience=consumer">FDA label information for this drug is available at DailyMed.</FDAExternalRef></DrugInfoMetaData><DrugInfoTitle>Durvalumab</DrugInfoTitle><Section id="_FDA"><Para><ExternalRef xref="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8baba4ea-2855-42fa-9bd9-5a7548d4cec3&amp;audience=consumer">FDA label information for this drug is available at DailyMed.</ExternalRef></Para></Section><Section id="_1"><Title>Use in Cancer</Title>                                                              
  <Para id="_2">Durvalumab
         is approved to treat adults with:</Para>                          
  <ItemizedList Style="bullet" id="_3">
   <ListItem><Strong><GlossaryTermRef href="CDR0000444968" dictionary="Cancer.gov" audience="Patient">bladder cancer</GlossaryTermRef></Strong> that has spread to the muscle. It is used with <GlossaryTermRef href="CDR0000508951" dictionary="Cancer.gov" audience="Patient">gemcitabine hydrochloride</GlossaryTermRef> and <GlossaryTermRef href="CDR0000045230" dictionary="Cancer.gov" audience="Patient">cisplatin</GlossaryTermRef> before surgery to remove the bladder and then alone after surgery.</ListItem><ListItem><Strong><GlossaryTermRef href="CDR0000559456" dictionary="Cancer.gov" audience="Patient">biliary tract</GlossaryTermRef> cancer</Strong>, including <GlossaryTermRef href="CDR0000335064" dictionary="Cancer.gov" audience="Patient">cholangiocarcinoma</GlossaryTermRef> and <GlossaryTermRef href="CDR0000446566" dictionary="Cancer.gov" audience="Patient">gallbladder cancer</GlossaryTermRef>, that has spread.  It is used with gemcitabine hydrochloride and cisplatin.</ListItem><ListItem><Strong><GlossaryTermRef href="CDR0000444987" dictionary="Cancer.gov" audience="Patient">endometrial cancer</GlossaryTermRef></Strong> that is <GlossaryTermRef href="CDR0000789741" dictionary="Cancer.gov" audience="Patient">mismatch repair deficient</GlossaryTermRef> (dMMR). It is used  with <GlossaryTermRef href="CDR0000045182" dictionary="Cancer.gov" audience="Patient">carboplatin</GlossaryTermRef> and <GlossaryTermRef href="CDR0000045258" dictionary="Cancer.gov" audience="Patient">paclitaxel</GlossaryTermRef> and then alone in patients with cancer that has spread or has come back.</ListItem><ListItem><Strong><GlossaryTermRef href="CDR0000046363" dictionary="Cancer.gov" audience="Patient">hepatocellular carcinoma</GlossaryTermRef></Strong> (a type of liver cancer) that cannot be removed by surgery. It is used with <GlossaryTermRef href="CDR0000559131" dictionary="Cancer.gov" audience="Patient">tremelimumab-actl</GlossaryTermRef>.</ListItem><ListItem><Strong><GlossaryTermRef href="CDR0000045323" dictionary="Cancer.gov" audience="Patient">non-small cell lung cancer</GlossaryTermRef></Strong> (NSCLC). It is used:<ItemizedList Style="bullet" id="_5"><ListItem>with <GlossaryTermRef href="CDR0000045841" dictionary="Cancer.gov" audience="Patient">platinum</GlossaryTermRef>-based chemotherapy before surgery and then alone after surgery in patients with cancer  that can be removed by surgery and does not have an abnormal <GeneName><GlossaryTermRef href="CDR0000796876" dictionary="Cancer.gov" audience="Patient">EGFR</GlossaryTermRef></GeneName> gene or <GeneName><GlossaryTermRef href="CDR0000721252" dictionary="Cancer.gov" audience="Patient">ALK</GlossaryTermRef></GeneName> gene</ListItem><ListItem>alone in patients with stage III cancer that cannot be removed by surgery but has not worsened after platinum-based chemotherapy and <GlossaryTermRef href="CDR0000044971" dictionary="Cancer.gov" audience="Patient">radiation therapy</GlossaryTermRef></ListItem><ListItem>with tremelimumab-actl and platinum-based chemotherapy in patients with cancer that has spread to other parts of the body and does not have an abnormal  <GeneName>EGFR</GeneName> gene or <GeneName>ALK</GeneName> gene</ListItem></ItemizedList></ListItem><ListItem><Strong><GlossaryTermRef href="CDR0000045327" dictionary="Cancer.gov" audience="Patient">small cell lung cancer</GlossaryTermRef>.</Strong> It is used:<ItemizedList Style="bullet" id="_6"><ListItem>alone in patients with <GlossaryTermRef href="CDR0000045910" dictionary="Cancer.gov" audience="Patient">limited-stage cancer</GlossaryTermRef> that did not get worse after
platinum-based chemotherapy given at the same time as radiation therapy</ListItem><ListItem>with <GlossaryTermRef href="CDR0000350228" dictionary="Cancer.gov" audience="Patient">etoposide phosphate</GlossaryTermRef> and either carboplatin or cisplatin as the first treatment in patients with <GlossaryTermRef href="CDR0000045911" dictionary="Cancer.gov" audience="Patient">extensive-stage</GlossaryTermRef> cancer</ListItem></ItemizedList></ListItem>
   </ItemizedList>
  <Para id="_4">Durvalumab
         is also being studied in the treatment of other types of
         cancer.</Para>
 </Section><Section id="_About"><Title>More About Durvalumab</Title><Para id="_Dict_1"><ExternalRef xref="https://www.cancer.gov/publications/dictionaries/cancer-drug/def/740856">Definition from the NCI Drug Dictionary</ExternalRef> - Detailed scientific definition and other names for this drug.</Para>

<Para id="_About_8.94">MedlinePlus Information on <ExternalRef xref="https://medlineplus.gov/druginfo/meds/a617030.html">Durvalumab</ExternalRef> - A lay language summary of important information about this drug that may include the following:</Para>
<ItemizedList Style="bullet" id="_About_9.95"><ListItem>warnings about this drug,</ListItem><ListItem>what this drug is used for and how it is used,</ListItem><ListItem>what you should tell your doctor before using this drug,</ListItem><ListItem>what you should know about this drug before using it, </ListItem><ListItem>other drugs that may interact with this drug, and</ListItem><ListItem>possible side effects.  </ListItem></ItemizedList><Para id="_About_10.96">Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for.  This patient information sheet applies only to approved uses of the drug.  However, much of the information may also apply to unapproved uses that are being studied.</Para></Section><Section id="_Research"><Title>Research Results and Related Resources</Title><Para><ExternalRef xref="https://www.cancer.gov/news-events/cancer-currents-blog/2024/head-neck-cancer-cetuximab-versus-durvalumab">Cetuximab Outperforms Durvalumab for Head and Neck Cancer When Cisplatin Isn’t an Option</ExternalRef></Para><Para><ExternalRef xref="https://www.cancer.gov/news-events/cancer-currents-blog/2024/endometrial-cancer-durvalumab-pembrolizumab-chemotherapy">More Immunotherapy Options Approved for Treating Endometrial Cancer</ExternalRef></Para><Para><ExternalRef xref="https://www.cancer.gov/news-events/cancer-currents-blog/2024/small-cell-lung-cancer-imfinzi-increases-survival">Durvalumab Extends Lives of People with Early-Stage Small Cell Lung Cancer</ExternalRef></Para><Para><ExternalRef xref="https://www.cancer.gov/news-events/cancer-currents-blog/2022/immunotherapy-myocarditis-cause">Study Identifies a Potential Cause of Immunotherapy’s Heart-Related Side Effects</ExternalRef></Para><Para><ExternalRef xref="https://www.cancer.gov/about-cancer/treatment/types/targeted-therapies">Targeted Therapy to Treat Cancer</ExternalRef></Para><Para><ExternalRef xref="https://www.cancer.gov/news-events/cancer-currents-blog/2021/immune-checkpoint-inhibitors-melanoma-long-term-side-effects">Study Details Long-Term Side Effects of Immune Checkpoint Inhibitors</ExternalRef></Para><Para><ExternalRef xref="https://www.cancer.gov/about-cancer/treatment/types/immunotherapy/monoclonal-antibodies">Monoclonal Antibodies</ExternalRef></Para><Para><ExternalRef xref="https://www.cancer.gov/about-cancer/treatment/types/immunotherapy/checkpoint-inhibitors">Immune Checkpoint Inhibitors</ExternalRef></Para></Section><Section id="_ClinicalTrial_1"><Title>Clinical Trials Accepting Patients</Title><Para id="_ClinicalTrial_2"><ExternalRef xref="https://www.cancer.gov/research/participate/clinical-trials/intervention/C103194">Find Clinical Trials for Durvalumab</ExternalRef> - Check for trials from NCI's list of cancer clinical trials now accepting patients.</Para></Section> 
  <DrugInfoDisclaimer>


<Para id="_Disclaimer_4"><Strong>Important: </Strong>The drug information on this page is meant to be educational. It is not a substitute for medical advice. The information may not cover all possible uses, actions, interactions, or side effects of this drug, or precautions to be taken while using it. Please see your health care professional for more information about your specific medical condition and the use of this drug.
</Para></DrugInfoDisclaimer> 
  <DateFirstPublished>2017-05-05</DateFirstPublished><DateLastModified>2025-04-07</DateLastModified></DrugInformationSummary>
